Stem definition | Drug id | CAS RN |
---|---|---|
5133 | 1257044-40-8 |
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
Sept. 20, 2019 | PMDA | AbbVie GK | |
Dec. 5, 2016 | EMA | AbbVie Ltd | |
April 11, 2016 | FDA | ABBVIE INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Death | 950.83 | 23.88 | 671 | 8821 | 334877 | 46341693 |
Off label use | 522.71 | 23.88 | 501 | 8991 | 379340 | 46297230 |
Chronic lymphocytic leukaemia | 419.61 | 23.88 | 101 | 9391 | 2799 | 46673771 |
Acute myeloid leukaemia | 404.25 | 23.88 | 143 | 9349 | 15635 | 46660935 |
Intentional product use issue | 400.62 | 23.88 | 201 | 9291 | 52579 | 46623991 |
Febrile neutropenia | 392.62 | 23.88 | 242 | 9250 | 94385 | 46582185 |
Neutropenia | 308.44 | 23.88 | 245 | 9247 | 142959 | 46533611 |
Tumour lysis syndrome | 302.88 | 23.88 | 95 | 9397 | 7141 | 46669429 |
Hospice care | 202.83 | 23.88 | 65 | 9427 | 5230 | 46671340 |
Sepsis | 128.69 | 23.88 | 148 | 9344 | 135866 | 46540704 |
Pancytopenia | 103.90 | 23.88 | 106 | 9386 | 84952 | 46591618 |
Thrombocytopenia | 102.01 | 23.88 | 127 | 9365 | 126454 | 46550116 |
Pneumonia | 91.05 | 23.88 | 221 | 9271 | 376099 | 46300471 |
Cytopenia | 90.93 | 23.88 | 40 | 9452 | 7728 | 46668842 |
Disease progression | 83.95 | 23.88 | 98 | 9394 | 91202 | 46585368 |
Neutrophil count decreased | 79.83 | 23.88 | 68 | 9424 | 43358 | 46633212 |
Acute myeloid leukaemia recurrent | 74.02 | 23.88 | 22 | 9470 | 1374 | 46675196 |
Platelet count decreased | 68.99 | 23.88 | 93 | 9399 | 99931 | 46576639 |
Infection | 68.58 | 23.88 | 108 | 9384 | 133484 | 46543086 |
Lymphadenopathy | 64.75 | 23.88 | 54 | 9438 | 33434 | 46643136 |
Mantle cell lymphoma | 57.54 | 23.88 | 15 | 9477 | 576 | 46675994 |
Bone marrow transplant | 55.67 | 23.88 | 15 | 9477 | 655 | 46675915 |
White blood cell count decreased | 55.19 | 23.88 | 89 | 9403 | 112142 | 46564428 |
Pyrexia | 51.85 | 23.88 | 172 | 9320 | 348630 | 46327940 |
Rhinovirus infection | 50.04 | 23.88 | 21 | 9471 | 3615 | 46672955 |
Pneumonia fungal | 47.32 | 23.88 | 21 | 9471 | 4139 | 46672431 |
Non-small cell lung cancer | 46.10 | 23.88 | 19 | 9473 | 3125 | 46673445 |
Blood lactate dehydrogenase increased | 45.84 | 23.88 | 36 | 9456 | 20464 | 46656106 |
Hyperuricaemia | 44.79 | 23.88 | 21 | 9471 | 4696 | 46671874 |
COVID-19 | 42.36 | 23.88 | 33 | 9459 | 18542 | 46658028 |
T-cell prolymphocytic leukaemia | 39.13 | 23.88 | 6 | 9486 | 10 | 46676560 |
Chronic lymphocytic leukaemia refractory | 38.35 | 23.88 | 7 | 9485 | 46 | 46676524 |
Myelodysplastic syndrome | 38.20 | 23.88 | 29 | 9463 | 15682 | 46660888 |
Terminal ileitis | 36.75 | 23.88 | 8 | 9484 | 139 | 46676431 |
Hospitalisation | 36.35 | 23.88 | 54 | 9438 | 63331 | 46613239 |
Drug ineffective | 35.53 | 23.88 | 52 | 9440 | 677786 | 45998784 |
Bone marrow failure | 34.39 | 23.88 | 36 | 9456 | 29633 | 46646937 |
Pain | 33.21 | 23.88 | 29 | 9463 | 476919 | 46199651 |
Diffuse large B-cell lymphoma | 31.86 | 23.88 | 18 | 9474 | 5920 | 46670650 |
Blood phosphorus increased | 31.32 | 23.88 | 14 | 9478 | 2805 | 46673765 |
Acute myeloid leukaemia refractory | 30.58 | 23.88 | 5 | 9487 | 15 | 46676555 |
Nonspecific reaction | 29.94 | 23.88 | 12 | 9480 | 1838 | 46674732 |
Febrile bone marrow aplasia | 29.44 | 23.88 | 18 | 9474 | 6844 | 46669726 |
Pleural effusion | 28.15 | 23.88 | 56 | 9436 | 82896 | 46593674 |
Allogenic stem cell transplantation | 27.77 | 23.88 | 4 | 9488 | 3 | 46676567 |
Transformation to acute myeloid leukaemia | 26.53 | 23.88 | 6 | 9486 | 125 | 46676445 |
Arthralgia | 25.55 | 23.88 | 22 | 9470 | 364581 | 46311989 |
Headache | 24.69 | 23.88 | 37 | 9455 | 478315 | 46198255 |
Aspergillus infection | 24.38 | 23.88 | 16 | 9476 | 6874 | 46669696 |
Campylobacter gastroenteritis | 24.31 | 23.88 | 7 | 9485 | 391 | 46676179 |
Fungal sepsis | 24.12 | 23.88 | 9 | 9483 | 1138 | 46675432 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Death | 1068.07 | 20.17 | 1149 | 15952 | 356134 | 29579243 |
Off label use | 826.33 | 20.17 | 850 | 16251 | 248440 | 29686937 |
Tumour lysis syndrome | 570.59 | 20.17 | 230 | 16871 | 12655 | 29922722 |
Chronic lymphocytic leukaemia | 566.52 | 20.17 | 176 | 16925 | 4452 | 29930925 |
Intentional product use issue | 539.85 | 20.17 | 306 | 16795 | 36134 | 29899243 |
Acute myeloid leukaemia | 531.10 | 20.17 | 241 | 16860 | 17765 | 29917612 |
Febrile neutropenia | 442.05 | 20.17 | 413 | 16688 | 106280 | 29829097 |
Neutropenia | 344.58 | 20.17 | 394 | 16707 | 128146 | 29807231 |
Hospice care | 299.79 | 20.17 | 108 | 16993 | 4344 | 29931033 |
Pneumonia | 144.89 | 20.17 | 468 | 16633 | 333838 | 29601539 |
Lymphadenopathy | 137.86 | 20.17 | 113 | 16988 | 24263 | 29911114 |
Cytopenia | 134.62 | 20.17 | 74 | 17027 | 8182 | 29927195 |
Disease progression | 131.69 | 20.17 | 193 | 16908 | 79681 | 29855696 |
Sepsis | 117.28 | 20.17 | 258 | 16843 | 146137 | 29789240 |
COVID-19 | 105.53 | 20.17 | 85 | 17016 | 17793 | 29917584 |
Mantle cell lymphoma | 102.26 | 20.17 | 37 | 17064 | 1504 | 29933873 |
Thrombocytopenia | 92.61 | 20.17 | 226 | 16875 | 136818 | 29798559 |
Infection | 90.73 | 20.17 | 161 | 16940 | 77913 | 29857464 |
Pancytopenia | 87.01 | 20.17 | 166 | 16935 | 84886 | 29850491 |
Chronic lymphocytic leukaemia recurrent | 85.80 | 20.17 | 24 | 17077 | 414 | 29934963 |
Lymphocyte count increased | 68.46 | 20.17 | 32 | 17069 | 2510 | 29932867 |
Hyperphosphataemia | 65.72 | 20.17 | 30 | 17071 | 2229 | 29933148 |
Autoimmune haemolytic anaemia | 65.10 | 20.17 | 36 | 17065 | 4023 | 29931354 |
Platelet count decreased | 63.23 | 20.17 | 167 | 16934 | 105962 | 29829415 |
Acute myeloid leukaemia recurrent | 56.08 | 20.17 | 24 | 17077 | 1528 | 29933849 |
Splenomegaly | 55.10 | 20.17 | 52 | 17049 | 13428 | 29921949 |
Neutrophil count decreased | 55.09 | 20.17 | 92 | 17009 | 42362 | 29893015 |
Transplant | 48.34 | 20.17 | 17 | 17084 | 635 | 29934742 |
Hospitalisation | 47.10 | 20.17 | 88 | 17013 | 44231 | 29891146 |
Blood phosphorus increased | 47.00 | 20.17 | 25 | 17076 | 2586 | 29932791 |
Pyrexia | 45.94 | 20.17 | 306 | 16795 | 294183 | 29641194 |
Toxicity to various agents | 45.78 | 20.17 | 22 | 17079 | 177161 | 29758216 |
Pneumonia fungal | 45.28 | 20.17 | 32 | 17069 | 5501 | 29929876 |
Completed suicide | 45.07 | 20.17 | 3 | 17098 | 99489 | 29835888 |
Acute myeloid leukaemia refractory | 42.97 | 20.17 | 8 | 17093 | 16 | 29935361 |
COVID-19 pneumonia | 41.24 | 20.17 | 28 | 17073 | 4512 | 29930865 |
Mantle cell lymphoma refractory | 41.23 | 20.17 | 10 | 17091 | 95 | 29935282 |
White blood cell count decreased | 40.08 | 20.17 | 122 | 16979 | 83825 | 29851552 |
Influenza | 35.17 | 20.17 | 77 | 17024 | 43321 | 29892056 |
Hyperuricaemia | 35.05 | 20.17 | 31 | 17070 | 7363 | 29928014 |
Chronic lymphocytic leukaemia transformation | 34.50 | 20.17 | 10 | 17091 | 197 | 29935180 |
Blood count abnormal | 33.17 | 20.17 | 37 | 17064 | 11615 | 29923762 |
Bone marrow transplant | 31.81 | 20.17 | 14 | 17087 | 954 | 29934423 |
Stem cell transplant | 31.72 | 20.17 | 18 | 17083 | 2113 | 29933264 |
Leukaemia | 31.55 | 20.17 | 21 | 17080 | 3276 | 29932101 |
Neutropenic sepsis | 30.39 | 20.17 | 35 | 17066 | 11374 | 29924003 |
Myelodysplastic syndrome | 30.31 | 20.17 | 45 | 17056 | 18733 | 29916644 |
Blood pressure increased | 30.26 | 20.17 | 3 | 17098 | 71925 | 29863452 |
Drug interaction | 30.18 | 20.17 | 42 | 17059 | 199526 | 29735851 |
Headache | 30.00 | 20.17 | 36 | 17065 | 182270 | 29753107 |
Skin infection | 29.60 | 20.17 | 26 | 17075 | 6118 | 29929259 |
Product dose omission issue | 29.35 | 20.17 | 8 | 17093 | 91623 | 29843754 |
Hypogammaglobulinaemia | 28.93 | 20.17 | 24 | 17077 | 5228 | 29930149 |
Depression | 28.77 | 20.17 | 8 | 17093 | 90429 | 29844948 |
Somnolence | 28.21 | 20.17 | 10 | 17091 | 96753 | 29838624 |
Overdose | 27.70 | 20.17 | 7 | 17094 | 84330 | 29851047 |
Blood uric acid abnormal | 27.69 | 20.17 | 7 | 17094 | 80 | 29935297 |
Lymphocytosis | 27.61 | 20.17 | 16 | 17085 | 1954 | 29933423 |
Bacteraemia | 27.60 | 20.17 | 39 | 17062 | 15521 | 29919856 |
Blood uric acid increased | 26.08 | 20.17 | 24 | 17077 | 5999 | 29929378 |
Chronic lymphocytic leukaemia refractory | 26.06 | 20.17 | 7 | 17094 | 103 | 29935274 |
Diffuse large B-cell lymphoma | 26.01 | 20.17 | 27 | 17074 | 7814 | 29927563 |
Blast cell count decreased | 25.88 | 20.17 | 4 | 17097 | 0 | 29935377 |
Pruritus | 25.77 | 20.17 | 18 | 17083 | 118186 | 29817191 |
Blood lactate dehydrogenase increased | 24.53 | 20.17 | 43 | 17058 | 20558 | 29914819 |
Escherichia bacteraemia | 24.25 | 20.17 | 17 | 17084 | 2885 | 29932492 |
Septic shock | 22.82 | 20.17 | 84 | 17017 | 63523 | 29871854 |
Soft tissue infection | 22.40 | 20.17 | 13 | 17088 | 1592 | 29933785 |
Blastic plasmacytoid dendritic cell neoplasia | 22.29 | 20.17 | 6 | 17095 | 89 | 29935288 |
Ureteric compression | 22.22 | 20.17 | 5 | 17096 | 33 | 29935344 |
Anxiety | 21.92 | 20.17 | 12 | 17089 | 89859 | 29845518 |
Condition aggravated | 21.85 | 20.17 | 28 | 17073 | 137838 | 29797539 |
Chemotherapy | 21.68 | 20.17 | 9 | 17092 | 531 | 29934846 |
Coronavirus infection | 21.41 | 20.17 | 17 | 17084 | 3481 | 29931896 |
Haemoglobin abnormal | 20.87 | 20.17 | 16 | 17085 | 3113 | 29932264 |
Respiratory tract infection | 20.62 | 20.17 | 34 | 17067 | 15472 | 29919905 |
T-cell prolymphocytic leukaemia | 20.57 | 20.17 | 5 | 17096 | 48 | 29935329 |
Lymphocyte count decreased | 20.43 | 20.17 | 38 | 17063 | 19017 | 29916360 |
Mantle cell lymphoma recurrent | 20.25 | 20.17 | 8 | 17093 | 415 | 29934962 |
Aspergillus infection | 20.22 | 20.17 | 27 | 17074 | 10187 | 29925190 |
Source | Code | Description |
---|---|---|
ATC | L01XX52 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Other antineoplastic agents |
FDA PE | N0000009176 | Increased Cellular Death |
MeSH PA | D000970 | Antineoplastic Agents |
FDA MoA | N0000185503 | P-Glycoprotein Inhibitors |
FDA EPC | N0000192515 | BCL-2 Inhibitor |
CHEBI has role | CHEBI:35610 | cytostatic |
CHEBI has role | CHEBI:68495 | type i programmed cell-death inducer |
CHEBI has role | CHEBI:133022 | bcl-2 inhibitor |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Chronic lymphoid leukemia, disease | indication | 92814006 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.0 | acidic |
pKa2 | 13.01 | acidic |
pKa3 | 7.73 | Basic |
pKa4 | 4.24 | Basic |
pKa5 | 3.47 | Basic |
pKa6 | 0.56 | Basic |
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
100MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | April 11, 2021 | NEW CHEMICAL ENTITY |
10MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | April 11, 2021 | NEW CHEMICAL ENTITY |
50MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | April 11, 2021 | NEW CHEMICAL ENTITY |
100MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | June 8, 2021 | INFORMATION ADDED TO THE PACKAGE INSERT REGARDING THE REVISION OF THE MONOTHERAPY INDICATION OF VENETOCLAX |
100MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | June 8, 2021 | REVISIONS TO INDICATION FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
10MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | June 8, 2021 | INFORMATION ADDED TO THE PACKAGE INSERT REGARDING THE REVISION OF THE MONOTHERAPY INDICATION OF VENETOCLAX |
10MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | June 8, 2021 | REVISIONS TO INDICATION FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
50MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | June 8, 2021 | INFORMATION ADDED TO THE PACKAGE INSERT REGARDING THE REVISION OF THE MONOTHERAPY INDICATION OF VENETOCLAX |
50MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | June 8, 2021 | REVISIONS TO INDICATION FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
100MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | Nov. 21, 2021 | VENETOCLAX IN COMBO WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY |
10MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | Nov. 21, 2021 | VENETOCLAX IN COMBO WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY |
50MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | Nov. 21, 2021 | VENETOCLAX IN COMBO WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY |
100MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | May 15, 2022 | VENETOCLAX IN COMBINULLTION WITH OBINUTUZUMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA |
10MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | May 15, 2022 | VENETOCLAX IN COMBINULLTION WITH OBINUTUZUMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA |
50MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | May 15, 2022 | VENETOCLAX IN COMBINULLTION WITH OBINUTUZUMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA |
100MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | April 11, 2023 | TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
10MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | April 11, 2023 | TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
50MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | April 11, 2023 | TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
100MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | Oct. 16, 2023 | REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY M15-656 (VIALE-A) AND M16-043 (VIALE-C) TO SUPPORT PMR 3545-1 AND PMR 3545-2 |
10MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | Oct. 16, 2023 | REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY M15-656 (VIALE-A) AND M16-043 (VIALE-C) TO SUPPORT PMR 3545-1 AND PMR 3545-2 |
50MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | Oct. 16, 2023 | REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY M15-656 (VIALE-A) AND M16-043 (VIALE-C) TO SUPPORT PMR 3545-1 AND PMR 3545-2 |
100MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | June 8, 2025 | INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
10MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | June 8, 2025 | INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
50MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | June 8, 2025 | INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
100MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | Nov. 21, 2025 | INDICATED IN COMBO WITH AZACITIDINE, OR DECITABINE, OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY |
10MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | Nov. 21, 2025 | INDICATED IN COMBO WITH AZACITIDINE, OR DECITABINE, OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY |
50MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | Nov. 21, 2025 | INDICATED IN COMBO WITH AZACITIDINE, OR DECITABINE, OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY |
100MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | May 15, 2026 | TREATMENT OF PREVIOUSLY UNTREATED ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) |
10MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | May 15, 2026 | TREATMENT OF PREVIOUSLY UNTREATED ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) |
50MG | VENCLEXTA | ABBVIE INC | N208573 | April 11, 2016 | RX | TABLET | ORAL | May 15, 2026 | TREATMENT OF PREVIOUSLY UNTREATED ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Apoptosis regulator Bcl-2 | Cytosolic other | INHIBITOR | Ki | 11 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Bcl-2-like protein 1 | Cytosolic other | INHIBITOR | Ki | 7.32 | SCIENTIFIC LITERATURE | ||||
Apoptosis regulator Bcl-W | Cytosolic other | INHIBITOR | Ki | 6.61 | SCIENTIFIC LITERATURE |
ID | Source |
---|---|
D10679 | KEGG_DRUG |
4035629 | VANDF |
C3641087 | UMLSCUI |
CHEBI:133021 | CHEBI |
LBM | PDB_CHEM_ID |
CHEMBL3137309 | ChEMBL_ID |
49846579 | PUBCHEM_CID |
C579720 | MESH_SUPPLEMENTAL_RECORD_UI |
9925 | INN_ID |
DB11581 | DRUGBANK_ID |
N54AIC43PW | UNII |
8318 | IUPHAR_LIGAND_ID |
1747556 | RXNORM |
240227 | MMSL |
31601 | MMSL |
d08429 | MMSL |
016803 | NDDF |
720491001 | SNOMEDCT_US |
763511000 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Venclexta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0074-0561 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 28 sections |
Venclexta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0074-0566 | TABLET, FILM COATED | 50 mg | ORAL | NDA | 28 sections |
Venclexta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0074-0576 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 28 sections |